Immunosuppressive drug therapy – biopharmaceutical challenges and remedies

Bibliography

• Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Re 1997;27:201–14
   PubMed Web of Science ®Google Scholar
• Wu CY, Benet LZ, Hebert MF, et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine. Clin Pharmacol Ther 1995;58:492–7
   PubMed Web of Science ®Google Scholar
• IMS Health. Business Insights August 2010. Available from: www.imshealth.com [Last accessed 27 January 2014]
   Google Scholar
• Rang HP, Dale MM, Ritter JM, et al. Pharmacology. 6th edition. Churchill Livingstone, Edinburgh; 2007. p. 207–45
   Google Scholar
• Khurana A, Brennan DC. Current concepts of immunosuppression and side effects. In: Pathology of solid organ transplantation. H. Liapis and H.L. Wang (eds.), Springer-Verlag Berlin Heidelberg; 2011. p. 11–30
   Google Scholar
• Beveridge T, Gratwohl A, Michot F, et al. Cyclosporine: pharmacokinetics after a single dose in man and serum levels after multiple dosing in recipients of allogenic bone-marrow grafts. Curr Ther Res 1981;30:5–18
   Web of Science ®Google Scholar
• Meinzer A, Muller E, Vonderscher J. Per orale Mikroemulsions- for mulierung Sandimmun Optoral/Neoral. In: Müller RH, Hilde-brandt GE, editors. Pharmazeutische Technologue: Moderne Arzneifor- men. Wissenschaftliche Verlagsgesellschaft, Stuttgart; 1998. p. 169–77
   Google Scholar
• Penkler L, Muller RH, Runge S, et al. Pharmaceutical Cyclosporine Formulation with Improved Biopharmaceutical Properties, Improved Physical Quality and Greater Stability, and Method for Producing Said Formulation. 1999 PCT Application PCT/EP99/02892 US6551619 B1; 1999
   Google Scholar
• Patel P, Patel H, Panchal S, et al. Formulation strategies for drug delivery of tacrolimus: an overview. Int J Pharm Investig 2012;2(4):169–75
   PubMedGoogle Scholar
• Rescue therapy with Mycophenolate Mofetil. The Mycophenolate Mofetil Renal Refractory Rejection Study Group. Clin Transplant 1996;10:131–5
   PubMed Web of Science ®Google Scholar
• Fisher RA, Ham JM, Marcos A, et al. A prospective randomized trial of mycophenolate mofetil with neoral or tacrolimus after orthotopic liver transplantation. Transplantation 1998;66:1616–21
   PubMed Web of Science ®Google Scholar
• Johnston A, He X, Holt DW. Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients. Transplantation 2006;82(11):1413–18
   PubMed Web of Science ®Google Scholar
• Bullingham R, Monroe S, Nicholls A, et al. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 1996;36:315–24
   PubMed Web of Science ®Google Scholar
• Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 2004;4:237–43
   PubMed Web of Science ®Google Scholar
• Vasquez EM. Sirolimus: a new agent for prevention of renal allograft rejection. Am J Health Syst Pharm 2000;57(5):437–48
   PubMed Web of Science ®Google Scholar
• Cho W, Kim MS, Kim JS, et al. Optimized formulation of solid self- microemulsifying sirolimus delivery systems. Int J Nanomedicine 2013;8:1673–82
   PubMed Web of Science ®Google Scholar
• Gabardi S, Baroletti SA. Everolimus: a Proliferation Signal Inhibitor with Clinical Applications in Organ Transplantation, Oncology, and Cardiology. Pharmacotherapy 2010;30(10):1044–56
   PubMed Web of Science ®Google Scholar
• Hebert MF, Roberts JP, Prueksaritanont T, et al. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992;52:453–7
   PubMed Web of Science ®Google Scholar
• Floren LC, Bekersky I, Benet LZ, et al. The effects of ketoconazole on the pharmacokinetic disposition of tacrolimus. Pharm Res 1996;13:S-411
   PubMedGoogle Scholar
• Laplanche R, Meno-Tetang GM, Kawai R. Physiologically Based Pharmacokinetic (PBPK) Modeling of Everolimus (RAD001) in Rats Involving Non-Linear Tissue Uptake. J Pharmacokinet Pharmacodyn 2007;34(3):373–400
   PubMed Web of Science ®Google Scholar
• Watkins PB, Wrighton SA, Schuetz EG, et al. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 1987;80:1029–36
   PubMed Web of Science ®Google Scholar
• Tamura S, Ohike A, Ibuki R, et al. Tacrolimus is a class-II low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. J Pharm Sci 2002;91:719–29
   PubMed Web of Science ®Google Scholar
• Simamora P, Alvarez JM, Yalkowsky SH. Solubilization of rapamycin. Int J Pharm 2001;213(1–2):25–9
   PubMed Web of Science ®Google Scholar
• Yu LX, Amidon GL. A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm 1999;186:119
   PubMed Web of Science ®Google Scholar
• Yu LX, Crison JR, Amidon GL. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. Int J Pharm 1996;140:111
   Web of Science ®Google Scholar
• Thomson AB, Schoeller C, Keelan M, et al. Lipid absorption: passing through the unstirred layers, brush-border membrane, and beyond. Can J Physiol Pharmacol 1993;71:531–55
   PubMed Web of Science ®Google Scholar
• Read NW, Barber DC, Levin RJ, et al. Unstirred layer and kinetics of electrogenic glucose absorption in the human jejunum in situ. Gut 1977;11:865–76
   Google Scholar
• Rowland M, Tozer TN. Drug Metabolism, Transport and the influence of Hepatic Disease. In: Clinical pharmacokinetics: concepts and applications. 3rd Edition Williams and Wilkins; Baltimore: 1995. p. 119–36
   Google Scholar
• Kolars JC, Schmiedlin-Ren P, Schuetz JD, et al. Identification of rifampin-inducible P450IIIA4 (CYP 3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871–8
   PubMed Web of Science ®Google Scholar
• Kolars JC, Awni WM, Merion RM, et al. First-pass metabolism of cyclosporine by the gut. Lancet 1991;338:1488–90
   PubMed Web of Science ®Google Scholar
• Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P-450 3A and P-glycoprotein have implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995;13:129–34
   PubMed Web of Science ®Google Scholar
• Benet LZ, Izumi T, Zhang Y, et al. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Control Release 1999;62:25–31
   PubMed Web of Science ®Google Scholar
• Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84:7735–8
   PubMed Web of Science ®Google Scholar
• Watkins PB. Drug metabolism by cytochromes P450 in the liver and small bowel. Gastroenterol Clin North Am 1992;21:511–26
   PubMed Web of Science ®Google Scholar
• Watkins PB, Leichtman A. The molecular basis of cyclosporine A metabolism, pharmacokinetics and drug interactions. Graft 1999;2:177–81
   Google Scholar
• Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997;64:36–42
   PubMed Web of Science ®Google Scholar
• Yatscoff RW, Wang P, Chan K, et al. Rapamycin: distribution, pharmacokinetics, and therapeutic range investigations. Ther Drug Monit 1995;1:666–71
   Google Scholar
• Cense HA, Eijck CH, Tilanus HW. New insights in the lymphatic spread of oesophageal cancer and its implications for the extent of surgical resection. Best Pract Res Clin Gastroenterol 2006;20:893–906
   PubMed Web of Science ®Google Scholar
• Arya M, Bott SR, Shergill IS, et al. The metastatic cascade in prostate cancer. Surg Oncol 2006;15:117–28
   PubMed Web of Science ®Google Scholar
• Trevaskis NL, Charman WN, Porter CJ. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev 2008;60:702–16
   PubMed Web of Science ®Google Scholar
• Srinivas TR, Meier-Kriesche HU. Minimizing Immunosuppression, an Alternative Approach to Reducing Side Effects: objectives and Interim Result. Clin J Am Soc Nephrol 2008;3:S101–16
   PubMed Web of Science ®Google Scholar
• Danovitch GM. Immunosuppressive medications and protocols. In: Danovitch GM, Handbook of kidney transplantation. Lippincott, Williams & Wilkins, Philadelphia; 2005. p. 72–134
   Google Scholar
• Hricik DE. Steroid-free immunosuppression in kidney transplantation: an editorial review. Am J Transplant 2002;2:19–24
   PubMed Web of Science ®Google Scholar
• Meier-Kriesche HU. Mycophenolate mofetil-based immunosuppressive minimization and withdrawal strategies in renal transplantation: possible risks and benefits. Curr Opin Nephrol Hypertens 2006;15(Suppl 1):S1–5
   PubMed Web of Science ®Google Scholar
• Porter C, Trevaskis N, Charman W. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 2007;6:231–48
   PubMed Web of Science ®Google Scholar
• Hauss DJ, Mehta S, Radebaugh GW. Targeted lymphatic transport and modified systemic distribution of CI-976, a lipophilic lipid-regulator drug, via a formulation approach. Int J Pharm 1994;108:85–93
   Web of Science ®Google Scholar
• Caliph SM, Charman WN, Porter CJ. Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. J Pharm Sci 2000;89:1073–84
   PubMed Web of Science ®Google Scholar
• O’Driscoll CM. Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci 2002;15:405–15
   PubMed Web of Science ®Google Scholar
• Muranishi S. Lymphatic delivery of drugs and its application to cancer chemotherapy. Yakugaku Zasshi 1980;100:687–98
   PubMed Web of Science ®Google Scholar
• Veld PA, Vetter RD, Lee RF, et al. Dietary fat inhibits the intestinal metabolism of the carcinogen benzo[a]pyrene in fish. J Lipid Res 1987;28:810–17
   PubMed Web of Science ®Google Scholar
• Vetter RD, Carey MC, Patton JS. Coassimilation of dietary fat and benzo(a)pyrene in the small intestine: an absorption model using the killifish. J Lipid Res 1985;26:428–34
   PubMed Web of Science ®Google Scholar
• Trevaskis NL, Porter CJH, Charman WN. The lymph lipid precursor pool is a key determinant of intestinal lymphatic drug transport. J Pharmacol Exp Ther 2006;316:881–91
   PubMed Web of Science ®Google Scholar
• Trevaskis NL, Porter CJH, Charman WN. An examination of the interplay between enterocyte-based metabolism and lymphatic drug transport in the rat. Drug Metab Dispos 2006;34:729–33
   PubMed Web of Science ®Google Scholar
• Porter CJ, Charman WN. Intestinal lymphatic drug transport: an update. Adv Drug Deliv Rev 2001;50:61–80
   PubMed Web of Science ®Google Scholar
• Shete H, Chatterjee S, De A, et al. Long chain lipid based tamoxifen NLC. Part II: pharmacokinetic, biodistribution and in vitro anticancer efficacy studies. Int J Pharm 2013;454(1):584–92
   PubMed Web of Science ®Google Scholar
• Oussoren C, Zuidema J, Crommelin DJ, et al. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid composition and lipid dose. Biochim Biophys Acta 1997;1328:261–72
   PubMed Web of Science ®Google Scholar
• Kaminskas LM, Porter CJ. Targeting the lymphatics using dendritic polymers (dendrimers). Adv Drug Deliv Rev 2011;63:890–900
   PubMed Web of Science ®Google Scholar
• Hawley AE, Davis SS, Illum L. Targeting of colloids to lymph nodes: influence of lymphatic physiology and colloidal characteristics. Adv Drug Deliv Rev 1995;17:129–48
   Web of Science ®Google Scholar
• Patel HM. Serum opsonins and liposomes: their interaction and opsonophagocytosis. Crit Rev Ther Drug Carrier Syst 1992;9:39–90
   PubMed Web of Science ®Google Scholar
• Charman WN, Stella VJ. Estimating the maximum potential for intestinal lymphatic transport of lipophilic drug molecules. Int J Pharm 1986;34:175–8
   Web of Science ®Google Scholar
• Khan AA, Mudassir J, Mohtar N, et al. Advanced drug delivery to the lymphatic system: lipid-based nanoformulations. Int J Nanomed 2013;8:2733–44
   PubMed Web of Science ®Google Scholar
• Bardelmeijer HA, Ouwehand M, Beijnen JH, et al. Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice. Invest New Drugs 2004;22:219–29
   PubMed Web of Science ®Google Scholar
• Varma MVS, Ashokraj Y, Dey CS, et al. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharm Res 2003;48:347–59
   Web of Science ®Google Scholar
• Shapiro AB, Ling V. Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. Biochem Pharmacol 1997;53:587–96
   PubMed Web of Science ®Google Scholar
• Gurunath S, Nanjwade BK, Patila PA. Enhanced solubility and intestinal absorption of candesartan cilexetil solid dispersions using everted rat intestinal sacs. Saudi Pharm J 2014;22(3):246–57
   PubMed Web of Science ®Google Scholar
• Komarov PG, Shtil AA, Buckingham LE, et al. Inhibition of cytarabine-induced MDR1 (P-glycoprotein) gene activation in human tumor cells by fatty acid-polyethylene glycol-fatty acid diesters, novel inhibitors of P-glycoprotein function. Int J Cancer 1996;68:245–50
   PubMed Web of Science ®Google Scholar
• Lo YL, Huang JD. Effects of sodium deoxycholate and sodium caprate on the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats. Biochem Pharmacol 2000;59:665–72
   PubMed Web of Science ®Google Scholar
• Zordan-Nudo T, Ling V, Liu Z, et al. Effects of non-ionic detergents on P-glycoprotein drug binding and reversal of multidrug resistance. Cancer Res 1993;53:5994–6000
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Li S, Miller DW, et al. Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers. Pharm Res 1999;16:1366–72
   PubMed Web of Science ®Google Scholar
• Sachs-Barrable K, Thamboo A, Lee SD, et al. Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of Rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 Cells. J Pharm Pharm Sci 2007;10(3):319–31
   PubMed Web of Science ®Google Scholar
• Hugger ED, Novak BL, Burton PS, et al. A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. J Pharm Sci 2002;91:1991–2002
   PubMed Web of Science ®Google Scholar
• Hugger ED, Andus KL, Brochardt RT. Effects of poly(ethylene glycol) on efflux transporter activity in Caco-2 monolayers. J Pharm Sci 2002;91:1980–90
   PubMed Web of Science ®Google Scholar
• Romsicki Y, Sharom FJ. The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter. Biochemistry 1999;38:6887–96
   PubMed Web of Science ®Google Scholar
• Woodcock DM, Linsenmeyer ME, Chojnowski G, et al. Reversal of multidrug resistance by surfactants. Br J Cancer 1992;66:62–8
   PubMed Web of Science ®Google Scholar
• Stormer E, von Moltke LL, Perloff MD, et al. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm Res 2002;19:1038–45
   PubMed Web of Science ®Google Scholar
• Beloqui A, Solinís MA, Gascón AR, et al. Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. J Control Release 2013;166:115–23
   PubMed Web of Science ®Google Scholar
• Christiansen A, Backensfeld T, Denner K, et al. Effects of non-ionic surfactants on cytochrome P450-mediated metabolism in vitro. Eur J Pharm Biopharm 2011;78(1):166–72
   PubMed Web of Science ®Google Scholar
• Johnson BM, Charman WN, Porter CJH. An In vitro examination of the impact of polyethylene glycol 400, pluronic p85, and vitamin E d-a-tocopheryl polyethylene glycol 1000 succinate on p- glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS PharmSci 2002;4(4):40
   PubMedGoogle Scholar
• Mountfield RJ, Senepin S, Schleimer M, et al. Potential inhibitory effects of formulation ingredients on intestinal cytochrome P450. Int J Pharm 2000;211(1–2):89–92
   PubMedGoogle Scholar
• Wang Y, Sun J, Zhang T, et al. Enhanced oral bioavailability of tacrolimus in rats by self-microemulsifying drug delivery systems. Drug Dev Ind Pharm 2011;37:1225–30
   PubMed Web of Science ®Google Scholar
• Duane WC, Ginsberg RL, Bennion LJ. Effects of fasting on bile acid metabolism and biliary lipid composition in man. J Lipid Res 1976;17:211–19
   PubMed Web of Science ®Google Scholar
• Nordskog BK, Phan CT, Nutting D F, et al. An examination of the factors affecting intestinal lymphatic transport of dietary lipids. Adv Drug Deliv Rev 2001;50:21–44
   PubMed Web of Science ®Google Scholar
• Narang A, Delmarre D, Gao D. Stable drug encapsulation in micelles and microemulsions. Int J Pharm 2007;345:9–25
   PubMed Web of Science ®Google Scholar
• Gershanik T, Benzeno S, Benita S. Interaction of the self-emulsifying lipid drug delivery system with mucosa of everted rat intestine as a function of surface charge and droplet size. Pharm Res 1998;15:863–9
   PubMed Web of Science ®Google Scholar
• Khoo SM, Humberstone AJ, Porter CJH, et al. Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine. Int J Pharm 1998;167:155–64
   Web of Science ®Google Scholar
• Kurowski M, Sternfield T, Sawyer A, et al. Pharmacokinetic and tolerability profile of twice–daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers. HIV Med 2003;4:94–100
   PubMedGoogle Scholar
• Vivek B, Hema N, Darshana H. Design and evaluation of self-microemulsifying drug delivery system (SMEDDS) of tacrolimus. AAPS Pharm Sci Tech 2008;9:13–21
   PubMed Web of Science ®Google Scholar
• Uner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine 2007;2:289–300
   PubMed Web of Science ®Google Scholar
• Muller RH, Runge S, Ravelli V, et al. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. Int J Pharm 2006;317(1):82–9
   PubMed Web of Science ®Google Scholar
• Patel PA, Patravale VB. AmbiOnp: solid lipid nanoparticles of amphotericin B for oral administration. J Biomed Nanotechnol 2011;7(5):632–9
   PubMed Web of Science ®Google Scholar
• Hu L, Tang X, Cui F. Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs. J Pharm Pharmacol 2004;56(12):1527–35
   PubMed Web of Science ®Google Scholar
• Zhang Z, Gao F, Bu H, et al. Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: in vitro characteristics and absorption mechanism in rats. Nanomedicine 2012;8:740–7
   PubMed Web of Science ®Google Scholar
• Muller H, Radtke M, Wissing S. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 2002;242:121–8
   PubMed Web of Science ®Google Scholar
• Zhang T, Chen J, Zhang Y, et al. Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide. Eur J Pharm Sci 2011;43:174–9
   PubMed Web of Science ®Google Scholar
• Zhuang C, Li N, Wanga M, et al. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm 2010;394:179–85
   PubMed Web of Science ®Google Scholar
• Tiwari R, Pathak K. Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int J Pharm 2011;415:232–43
   PubMed Web of Science ®Google Scholar
• Huynh NT, Passirani C, Saulnier P, et al. Lipid nanocapsules: a new platform for nanomedicine. Int J Pharm 2009;379:201–9
   PubMed Web of Science ®Google Scholar
• Malan Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 2009;30:592–9
   PubMed Web of Science ®Google Scholar
• Lee SH, Choi SH, Kim SH, et al. Thermally sensitive cationic polymer nanocapsules for specific cytosolic delivery and efficient gene silencing of siRNA: swelling induced physical disruption of endosome by cold shock. J Control Release 2008;125:25–32
   PubMed Web of Science ®Google Scholar
• Khalid MN, Simard P, Hoarau D, et al. Long circulating poly(ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumors. Pharm Res 2006;23:752–8
   PubMed Web of Science ®Google Scholar
• Peltier S, Oger JM, Lagarce F, et al. Enhanced Oral Paclitaxel Bioavailability After Administration of Paclitaxel-Loaded Lipid Nanocapsules. Pharm Res 2006;23(6):1243–50
   PubMed Web of Science ®Google Scholar
• Lamprecht A, Saumet JL, Roux J, et al. Lipid nanocarriers as drug delivery system for ibuprofen in pain treatment. Int J Pharm 2004;278:407–14
   PubMed Web of Science ®Google Scholar
• Ramadan A, Lagarce F, Tessier-Marteau A, et al. Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study. Int J Nanomedicine 2011;6:2941–51
   PubMed Web of Science ®Google Scholar
• Nassar T, Rom A, Nyska A, et al. A novel nanocapsule delivery system to overcome intestinal degradation and drug transport limited absorption of P-glycoprotein substrate. Drugs Pharm Res 2008;25:2019–29
   PubMed Web of Science ®Google Scholar
• Attili-Qadria S, Karraa N, Nemirovskia A, et al. Oral delivery system prolongs blood circulation of docetaxel nanocapsules via lymphatic absorption. Proc Natl Acad Sci 2013;110(43):17498–503
   PubMed Web of Science ®Google Scholar
• Yang X, Zhao L, Almasy L, et al. Preparation and characterization of 4-dedimethylamino sancycline (CMT-3) loaded nanostructured lipid carrier (CMT-3/NLC) formulations. Int J Pharm 2013;450:225–34
   PubMed Web of Science ®Google Scholar